AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 20. (Canceled)

21. (Previously Presented) A method improving reproducibility of insulin delivered by inhalation, comprising:

measuring a patient's glucose level;

aerosolizing a formulation comprising monomeric insulin present in a disposable container comprising a porous membrane by moving the formulation through the porous membrane;

inhaling the aerosolized formulation into the lungs of the patient in a manner which allows aerosolized particles of the insulin to deposit on the lung tissue; and

repeating the measuring, aerosolizing, inhaling in a manner so as to maintain the patient's glucose level in a desired range;

wherein pores of the porous membrane have a cross-sectional configuration with a small end opening of 0.25 to 6.0 microns in diameter and a large end opening of 2.0 to 20 times the diameter of the small end.

22. (Previously Presented) The method of claim 21, wherein the monomeric insulin is insulin lispro.

23. (Previously Presented) The method of claim 21, wherein each aerosolizing is carried out to create an aerosolized dose containing substantially the same amount of insulin.

24. (Previously Presented) The method of claim 21, wherein the inhaling is repeated with different inhaled volumes of air.

25. (Previously Presented) The method of claim 21, further comprising:

orally administering a sulfonylurea drug to the patient.

26. (Previously Presented) The method of claim 25, wherein the sulfonylurea drug is chosen from acetohexamide, chlorpropamide, tolazamide, tolbutamide, glipzide and glyburide.

27. (Previously Presented) The method of claim 25, wherein the monomeric insulin is insulin lispro.

28. (Previously Presented) The method of claim 21, further comprising:

heating air surrounding the aerosolized formulation.

29. (Previously Presented) The method of claim 21, wherein the aerosolized particles have a diameter in the range of about 1.0 to about 4.0 microns.

30. (Canceled)

31. (Previously Presented) The method of claim 21, wherein the formulation is a liquid formulation comprised of a pharmaceutically acceptable carrier and insulin.

32. (Previously Presented) A method of claim 21, further comprising:

measuring the inhaled volume of air; and

providing a signal when the inhaled volume of reaches 65% or more of lung capacity of the lungs of the inhaling patient.

33. (Previously Presented) The method of claim 32, where the signal is provided when the inhaled volume reaches 80% more of lung capacity of the lungs of the inhaling patient.